36 related articles for article (PubMed ID: 17302859)
1. Immunotherapy strategies for multiple myeloma: the present and the future.
Locke FL; Nishihori T; Alsina M; Kharfan-Dabaja MA
Immunotherapy; 2013 Sep; 5(9):1005-20. PubMed ID: 23998734
[TBL] [Abstract][Full Text] [Related]
2.
Khalaf WS; Garg M; Mohamed YS; Stover CM; Browning MJ
Front Immunol; 2019; 10():1792. PubMed ID: 31428094
[TBL] [Abstract][Full Text] [Related]
3. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
[TBL] [Abstract][Full Text] [Related]
4. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.
Danylesko I; Beider K; Shimoni A; Nagler A
Clin Dev Immunol; 2012; 2012():753407. PubMed ID: 22649466
[TBL] [Abstract][Full Text] [Related]
5. Novel immunotherapies.
Yi Q
Cancer J; 2009; 15(6):502-10. PubMed ID: 20010170
[TBL] [Abstract][Full Text] [Related]
6. Cellular immunotherapy for multiple myeloma.
Rosenblatt J; Avigan D
Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
[TBL] [Abstract][Full Text] [Related]
7. Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro.
Cywinski AL; Dunnion DJ; Teobald I; Tucker VC; Browning MJ
Tissue Antigens; 2006 Aug; 68(2):115-26. PubMed ID: 16866881
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of human hybrid cell lines generated by fusion of B-lymphoblastoid cells and ex vivo tumour cells as candidate vaccines for haematological malignancies.
Mohamed YS; Dunnion D; Teobald I; Walewska R; Browning MJ
Vaccine; 2012 Oct; 30(46):6578-87. PubMed ID: 22939910
[TBL] [Abstract][Full Text] [Related]
9. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro.
Mohamed YS; Dunnion D; Teobald I; Walewska R; Browning MJ
Immunobiology; 2012 Jul; 217(7):719-29. PubMed ID: 22305004
[TBL] [Abstract][Full Text] [Related]
10. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation.
Vasir B; Borges V; Wu Z; Grosman D; Rosenblatt J; Irie M; Anderson K; Kufe D; Avigan D
Br J Haematol; 2005 Jun; 129(5):687-700. PubMed ID: 15916692
[TBL] [Abstract][Full Text] [Related]
11. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
Raje N; Hideshima T; Davies FE; Chauhan D; Treon SP; Young G; Tai YT; Avigan D; Gong J; Schlossman RL; Richardson P; Kufe DW; Anderson KC
Br J Haematol; 2004 May; 125(3):343-52. PubMed ID: 15086415
[TBL] [Abstract][Full Text] [Related]
12. Preclinical development of hybrid cell vaccines for multiple myeloma.
Walewska R; Teobald I; Dunnion D; Abdulmajed H; Aldred M; Sadler J; Chapman C; Browning M
Eur J Haematol; 2007 Jan; 78(1):11-20. PubMed ID: 17302859
[TBL] [Abstract][Full Text] [Related]
13. Vaccination therapy with tumor-dendritic cell hybrids: a promising therapeutic approach?
Haenssle HA
Curr Opin Investig Drugs; 2005 Dec; 6(12):1240-5. PubMed ID: 16370389
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
